IGFBPL1 Peptide-Centric Chimeric Antigen Receptor Autologous T Cells for Relapsed HLA-A*02 Neuroblastoma and Medulloblastoma |
Children’s Hospital of Philadelphia / John Maris, MD |
Reach Grants |
2024 |
Pennsylvania |
Overcoming Menin-inhibitor resistance
|
Children’s Hospital of Philadelphia / Kathrin Bernt, MD |
Reach Grants |
2024 |
Pennsylvania |
Targeting protein synthesis in pediatric acute myeloid leukemia |
Cincinnati Children's Hospital Medical Center / Courtney Jones, PhD |
'A' Award Grants |
2024 |
Ohio |
Uncovering new approaches to target FOXR2 in pediatric cancers |
Children’s Hospital Los Angeles / Jessica Tsai, MD/PhD |
'A' Award Grants |
2024 |
California |
Collective cell invasion of fusion positive rhabdomyosarcoma regulated by PAX3-FOXO1 |
Children’s Hospital Los Angeles / Jinseok Park, PhD |
'A' Award Grants |
2024 |
California |
Systematic screening of receptor pairs combinations for improving solid tumor cancer immunotherapy |
Baylor College of Medicine / Xavier Rios, MD/PhD |
'A' Award Grants |
2024 |
Texas |
Targeting Novel Inflammatory Signaling Pathways in Juvenile Myelomonocytic Leukemia |
Indiana University / Santhosh Kumar Pasupuleti, PhD |
'A' Award Grants |
2024 |
Indiana |
Gene-mediated cytotoxic immunotherapy in pediatric patients with recurrent malignant brain tumors |
University of Michigan / Andrea Franson, MD |
'A' Award Grants |
2024 |
Michigan |
Targeting the immunosuppressive effects of Myc-hyperactivation in high-risk osteosarcoma |
Emory University / Jason Yustein, MD/PhD |
Innovation Grants |
2024 |
Georgia |
Development of allogeneic off-the-shelf gamma delta T cell product for pediatric AML |
Baylor College of Medicine / Norihiro Watanabe, PhD |
Innovation Grants |
2024 |
Texas |